N6-mA levels are significantly increased in aggressive forms of cancer, making it a novel therapeutic target and a powerful diagnostic marker.
Dr. Xiao’s lab at Yale is developing chemical inhibitors against methyltransferases and readers of N6-mA and testing these inhibitors in biochemical assays and patient derived xenograft (PDX) mouse models.
Several lead compounds have been identified. Medicinal chemistry optimization and large scale screen is in progress.
Intellectual Property: US Patent Application pending
